3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
79
Carboplatin
64
Bevacizumab
33
liposomal doxorubicin
29
Topotecan
28
Gemcitabine
25
Cisplatin
19
olaparib
18
Drug Therapy
12
Doxorubicin
12
Taxes
11
niraparib
9
Docetaxel
6
CP protocol
6
Trabectedin
5
Hyperthermic Intraperitoneal Chemotherapy
5
Etoposide
5
Cyclophosphamide
5
1-dodecylpyridoxal
5
rucaparib
4
pembrolizumab
4
avelumab
4
atezolizumab
4
Immunoglobulin G
4
Ifosfamide
4
Disulfides
4
Dexamethasone
4
Chemotherapy, Adjuvant
4
trebananib
3
fluzoparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Ovarian Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled